» Articles » PMID: 25328867

Overactive Bladder in the Vulnerable Elderly

Overview
Journal Res Rep Urol
Publisher Dove Medical Press
Specialty Urology
Date 2014 Oct 21
PMID 25328867
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Overactive bladder (OAB) is a common problem that may occur in individuals of all ages. It has a considerable impact on patient quality of life, and although moderately effective management strategies do exist, this condition often remains undiagnosed and untreated. OAB needs to be viewed as a symptom complex. Its presentation and management are complicated in the vulnerable elderly by the presence of baseline frailty and multiple coexisting chronic conditions. Furthermore, and beyond a simple understanding of symptomatology, providers must address patient goals and motivations as well as the expectations of caretakers. These multiple levels of perception, function, expectations, and treatment efficacy/risks must be tailored to the individual patient. While the vulnerable elderly patient may often have evidence of urinary tract dysfunction, OAB and urge urinary incontinence in this population must be understood as a multifactorial geriatric syndrome and viewed in the context of medical and functional baseline and precipitating risk factors. Expectations and goals must be tailored to the resources of vulnerable elderly patients and their caregivers, and care must be coordinated with other medical care providers. The management of OAB in the vulnerable elderly often poses significant management challenges. Nonetheless, with a thoughtful approach and an aim towards future research specifically for this population, significant reductions in morbidity and mortality long with enhancement in health-related quality of life are possible.

Citing Articles

Polychlorinated biphenyl (PCB) exposure in adult female mice can influence bladder contractility.

Lavery T, Spiegelhoff A, Wang K, Kennedy C, Ridlon M, Keil Stietz K Am J Clin Exp Urol. 2023; 11(5):367-384.

PMID: 37941647 PMC: 10628623.


Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB).

Khizer Z, Akram M, Tahir M, Liu W, Lou S, Conway B Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986471 PMC: 10056888. DOI: 10.3390/ph16030372.


Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder.

Heesakkers J, Te Dorsthorst M, Wagg A Can Geriatr J. 2022; 25(1):72-78.

PMID: 35310472 PMC: 8887709. DOI: 10.5770/cgj.25.530.


A non-interventional cross-sectional re-contact study investigating the relationship between overactive bladder and frailty in older adults in Japan.

Yoshida M, Satake S, Ishida K, Tanaka Y, Ukai M BMC Geriatr. 2022; 22(1):68.

PMID: 35062875 PMC: 8783467. DOI: 10.1186/s12877-022-02756-7.


Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting.

Amiri M, Schneider T, Oelke M, Murgas S, Michel M J Clin Med. 2021; 10(2).

PMID: 33467690 PMC: 7830207. DOI: 10.3390/jcm10020311.


References
1.
Wagg A, Verdejo C, Molander U . Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010; 64(9):1279-86. DOI: 10.1111/j.1742-1241.2010.02449.x. View

2.
Coyne K, Sexton C, Irwin D, Kopp Z, Kelleher C, Milsom I . The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008; 101(11):1388-95. DOI: 10.1111/j.1464-410X.2008.07601.x. View

3.
Sakakibara R, Panicker J, Fowler C, Tateno F, Kishi M, Tsuyusaki Y . Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol. 2013; 21(1):33-8. DOI: 10.1111/iju.12288. View

4.
Gormley E, Lightner D, Burgio K, Chai T, Clemens J, Culkin D . Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012; 188(6 Suppl):2455-63. DOI: 10.1016/j.juro.2012.09.079. View

5.
Wagg A, Cardozo L, Nitti V, Castro-Diaz D, Auerbach S, Blauwet M . The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014; 43(5):666-75. DOI: 10.1093/ageing/afu017. View